恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

午间休市 09-09 12:05:00

45.780

-0.540

-1.17%

最高46.820	最低45.500	成交量77.92万
今开46.520	昨收46.320	日振幅2.85%
总市值3,038亿	流通市值118.11亿	总股本66.37亿
成交额3,572万	换手率0.30%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":45.78,"timestamp":1788926700003,"preClose":46.32,"halted":0,"volume":779246,"delay":0,"changeRate":-0.011658031088082882,"floatShares":258000000,"shares":6637000000,"eps":1.3800999121651296,"marketStatus":"午间休市","change":-0.54,"latestTime":"09-09 12:05:00","open":46.52,"high":46.82,"low":45.5,"amount":35716731,"amplitude":0.028497,"askPrice":45.78,"askSize":400,"bidPrice":45.76,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":1.3610241243961354,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788930000000},"marketStatusCode":3,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":46.32,"dividendRate":0.005097,"openAndCloseTimeList":[[1788917400000,1788926400000],[1788930000000,1788940800000]],"volumeRatio":0.495048,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":44.79,"timestamp":1788924602000,"preClose":45.71,"halted":0,"volume":45482100,"delay":0,"premium":"-12.61"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2665037334","title":"百亿基金经理最新调仓：杨宗昌增持颀中科技，葛兰减仓恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2665037334","media":"澎湃新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665037334?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:52","pubTimestamp":1788871920,"startTime":"0","endTime":"0","summary":"随着近期上市公司回购公告的密集披露，易方达基金杨宗昌、易方达基金陈皓、兴证全球基金杨世进、景顺长城基金农冰立、中欧基金葛兰、博道基金杨梦等十多位百亿基金经理的最新调仓路径曝光。整体来看，部分基金经理在ST绝味、崇达技术、颀中科技等标的上选择加仓或新进；与此同时，恒瑞医药、佰维存储等个股则遭阶段性减持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286826.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828557.USD","BK0188","LU0359201885.HKD","LU1969619763.USD","LU2097828474.EUR","LU1781817850.SGD","LU2289578879.USD","BK0239","LU1023057109.AUD","LU1997245094.SGD","LU1820825898.SGD","BK0028","LU2097828714.EUR","LU2328871848.SGD","LU1064130708.USD","BK0196","LU2580892789.USD","LU1328615791.USD","688352","LU1064131003.USD","LU2148510915.USD","BK0183","LU1255011170.USD","BK0012","LU1997244956.HKD","LU0359201612.USD","LU2495084118.USD","LU2543165471.USD","LU2488822045.USD","01276","600276","LU0405327148.USD","LU1580142542.USD","LU1655091616.SGD","LU2580892862.HKD","BK0214","LU1146622755.USD","BK0060","BK1191","LU2097828805.USD","LU2097828631.EUR","LU1997245177.USD","LU0359202008.SGD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158076338","title":"恒瑞医药(01276)将于9月24日召开股东大会 重点审议A股持股计划与H股回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1158076338","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158076338?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:45","pubTimestamp":1788867930,"startTime":"0","endTime":"0","summary":"恒瑞医药发布公告，拟于2026年9月24日14:30在上海浦东新区海科路1288号召开2026年第一次临时股东大会，股权登记日同日，H股过户登记将自9月21日至24日暂停。\\n2. 特别决议：审议2026年H股股份计划及授权董事会或管理人执行；同时授予董事会一般授权，可回购不超过当日已发行H股总数10%的股份。未登记股东须在9月18日16:30前完成过户，股东可委派代表出席，交通与住宿费用自理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181298014","title":"恒瑞医药拟回购已发行股份10%，董事会获授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1181298014","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181298014?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:41","pubTimestamp":1788867715,"startTime":"0","endTime":"0","summary":"恒瑞医药近日发布公告称，拟向股东大会申请授权回购公司不超过已发行H股股份总数10%的股份。公司目前在香港联交所已发行约2.58亿股H股，若授权获得批准，回购上限约为2581.98万股。恒瑞医药表示，此次回购所需资金将来自公司符合中国法律及公司章程规定的自有资金，董事会认为执行股份购回计划将有助于维护股东整体权益。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药拟回购已发行股份10%，董事会获授权","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132034507","title":"恒瑞医药(01276)发布公告 拟于2026年9月24日召开2026年第一次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=1132034507","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132034507?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:11","pubTimestamp":1788865916,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司9月8日在上海证券交易所及香港联交所发布公告，拟于2026年9月24日召开2026年第一次临时股东大会。此次股东大会由公司董事会召集，采用现场投票与上海证券交易所股东大会网络投票系统相结合的方式进行。现场会议定于2026年9月24日14时30分在公司位于上海市浦东新区海科路1288号的会议室召开。与公司2026年A股员工持股计划及2026年H股股份计划存在利害关系的关联股东需回避相关议案的表决。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665769093","title":"【千亿药企龙头深度拆解】恒瑞医药：转型阵痛与长期价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2665769093","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665769093?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:25","pubTimestamp":1788855900,"startTime":"0","endTime":"0","summary":"0127款1类新药筑底，创新转型进入“深水区”恒瑞是国内创新药领域公认的标杆企业之一。截至目前，公司已在中国成功获批27款1类创新药、6款2类新药，创新药获批数量、管线丰富度、临床转化效率均为内资药企顶尖水平。上半年共取得创新药制剂生产批件7个、药物临床批件67个，同时斩获6项CDE突破性治疗品种认定、3项优先审评品种认定。仿创切换的阵痛，叠加部分肿瘤大单品受医保续约降价、竞争加剧影响，共同压低了整体营收增速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514125&idx=1&sn=f27d422a1eed79081d0f4326eebf0fcf&chksm=f3e4af8980a8b13eb7d9c7e6ba2f7adb53b16831db947d8a141ebc34229e9a2f44f7e837e62e&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0359201612.USD","LU1023057109.AUD","01276","LU0359202008.SGD","BK1191","LU0359201885.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124754022","title":"恒瑞医药（01276）将于2026年9月24日召开第一次临时股东大会并暂停H股过户","url":"https://stock-news.laohu8.com/highlight/detail?id=1124754022","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124754022?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:01","pubTimestamp":1788778884,"startTime":"0","endTime":"0","summary":"江蘇恒瑞醫藥股份有限公司9月7日公告称，公司计划于2026年9月24日14时30分在中国上海市浦东新区海科路1288号召开2026年第一次临时股东大会，审议包括拟采纳“2026年H股股份计划”在内的相关事项。为确定有权出席是次股东大会的H股股东名册，恒瑞医药将于2026年9月21日至2026年9月24日期间暂停办理H股股份过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665316750","title":"恒瑞医药一日4款在研药获批临床：肿瘤两款、减重两款，双赛道同步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2665316750","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665316750?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:55","pubTimestamp":1788778526,"startTime":"0","endTime":"0","summary":"9月7日盘后，恒瑞医药（SH600276，股价46.26元，市值3055.72亿元）一口气披露了共三份涉及四种药物的临床试验获批公告。公告分别涉及HRS-6209胶囊、HRS-4508片、SHR-1179注射液以及HRS-1597片四款在研药物，覆盖抗肿瘤与体重管理两大热门赛道，研发管线推进节奏稳健。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866827539.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866827539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2289578879.USD","LU1064130708.USD","LU2543165471.USD","LU1997245094.SGD","LU2097828474.EUR","LU2097828631.EUR","LU1580142542.USD","LU1997244956.HKD","LU1023057109.AUD","LU1997245177.USD","LU0405327494.USD","LU2097828557.USD","LU1146622755.USD","LU1064131003.USD","LU1781817850.SGD","LU2580892789.USD","BK1191","LU2495084118.USD","BK0012","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","BK0183","LU2580892862.HKD","BK0239","LU1820825898.SGD","BK0188","LU0359202008.SGD","600276","LU2148510915.USD","LU2097828805.USD","BK0060","BK0196","01276","LU2097828714.EUR","LU1655091616.SGD","BK0028","LU0359201885.HKD","LU1255011170.USD","LU0405327148.USD","LU1328615791.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174599684","title":"恒瑞医药(01276)获批开展SHR-1179注射液体重管理临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1174599684","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174599684?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:51","pubTimestamp":1788778312,"startTime":"0","endTime":"0","summary":"2026年9月7日，恒瑞医药公告，其子公司广东恒瑞医药有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》。该批件同意公司自主研发的1类生物制品SHR-1179注射液开展体重管理适应症的临床试验。公告显示，SHR-1179注射液的临床试验申请受理号为CXSL2600586，国家药监局于2026年6月1日受理并完成审评，认定该申请符合药品注册有关要求。恒瑞医药称，截至目前，SHR-1179注射液项目已累计投入研发费用约2,420万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173635304","title":"恒瑞医药子公司HRS-1597片获国家药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1173635304","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173635304?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:46","pubTimestamp":1788777973,"startTime":"0","endTime":"0","summary":"2026年9月7日，恒瑞医药公告称，其子公司山东盛迪医药有限公司已收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展HRS-1597片用于体重管理适应症的临床试验。据公告，HRS-1597片为公司自主研发的1类新药，目前国内外暂无同类药物获批上市。截至公告披露日，HRS-1597片项目已累计投入研发费用约1,690万元。恒瑞医药表示将按国家相关规定推进项目并及时披露后续进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665631661","title":"恒瑞医药(01276.HK)：HRS-1597片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665631661","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665631661?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:44","pubTimestamp":1788777887,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023057109.AUD","LU0359201885.HKD","LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD","01276","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113917648","title":"港交所披露：贝莱德对江苏恒瑞医药H股好仓比例9月2日由5.92%升至7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113917648","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113917648?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:48","pubTimestamp":1788774494,"startTime":"0","endTime":"0","summary":"港交所最新权益披露资料显示，全球资管巨头贝莱德于9月2日增持了江苏恒瑞医药的H股股份，其好仓持股比例从此前的5.92%显著攀升至7.21%。这一变动反映出机构投资者对这家中国制药龙头企业的持续看好与配置加码。具体来看，贝莱德在恒瑞医药H股上的持仓规模实现了跨越式增长。后续贝莱德是否会进一步增持，以及恒瑞医药H股在港股市场的表现将如何演绎，均有待时间给出答案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","BK0183","BK0060","LU1580142542.USD","LU1997245094.SGD","BK1191","LU2580892789.USD","LU2097828474.EUR","LU2148510915.USD","LU1064130708.USD","LU1146622755.USD","LU1255011170.USD","LU0359201612.USD","BK0012","LU2328871848.SGD","LU0405327148.USD","BK0196","BK0188","LU2097828631.EUR","LU1997244956.HKD","LU1781817850.SGD","LU0359202008.SGD","LU2580892862.HKD","LU2097828557.USD","LU2495084118.USD","LU2097828714.EUR","BK0239","BK0028","LU1820825898.SGD","600276","LU1064131003.USD","LU2289578879.USD","01276","LU1328615791.USD","LU0405327494.USD","LU2488822045.USD","LU1655091616.SGD","LU1969619763.USD","LU0359201885.HKD","LU2097828805.USD","LU1023057109.AUD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313519","title":"恒瑞医药(600276.SH)子公司HRS-1597片获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665313519?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:18","pubTimestamp":1788772689,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1597片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1597片是公司自主研发的1类新药，拟用于体重管理。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1597片相关项目累计研发投入约1690万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","IBBJ","MDTX","LU2097828631.EUR","LU2580892862.HKD","LU0405327494.USD","LU2289578879.USD","LU1997245094.SGD","LU1580142542.USD","LU2495084118.USD","BK0239","LU0359201885.HKD","LU2097828714.EUR","LU2543165471.USD","LU2580892789.USD","BK0188","LU1781817850.SGD","LU1997244956.HKD","LU2097828805.USD","BK0196","BK0012","IBBQ","LU1328615791.USD","BK1191","BMED","BK0183","LU0359201612.USD","LU1255011170.USD","LU1820825898.SGD","LU1655091616.SGD","LU2097828474.EUR","LU1064130708.USD","LU1146622755.USD","LU0359202008.SGD","LU1969619763.USD","LU2488822045.USD","LU1023057109.AUD","LU0405327148.USD","LU2148510915.USD","BK0060","600276","BK0028","LU1997245177.USD","LU2328871848.SGD","PSYK","LU1064131003.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318079","title":"恒瑞医药：自主研发1类生物制品SHR1179注射液获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318079","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665318079?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:03","pubTimestamp":1788771780,"startTime":"0","endTime":"0","summary":"9月7日，恒瑞医药（600276/01276）发布公告，公司子公司广东恒瑞药有限公司收到国家药品监督管理局核准签发的关于SHR-1179注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物为公司自主研发的治疗用1类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179注射液相关项目累计研发投入约为2420万元（未经审计）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866736252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866736252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1255011170.USD","LU0359201612.USD","LU2580892789.USD","LU2097828631.EUR","BK0183","LU2289578879.USD","600276","LU2580892862.HKD","LU0405327148.USD","BK0060","BK0028","LU0405327494.USD","LU1146622755.USD","LU1997245177.USD","LU2097828474.EUR","LU1328615791.USD","LU0359201885.HKD","LU1997245094.SGD","BK0012","LU2148510915.USD","BK0188","BK0196","LU1655091616.SGD","LU2328871848.SGD","LU2488822045.USD","BK1191","LU2097828557.USD","LU2097828714.EUR","LU1820825898.SGD","LU2097828805.USD","LU2495084118.USD","LU1064131003.USD","LU1023057109.AUD","LU1064130708.USD","LU1969619763.USD","LU1781817850.SGD","LU2543165471.USD","LU0359202008.SGD","LU1997244956.HKD","01276","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665181063","title":"恒瑞医药：HRS-6209胶囊、HRS-4508片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665181063","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665181063?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:47","pubTimestamp":1788770820,"startTime":"0","endTime":"0","summary":"南财智讯9月7日电，恒瑞医药公告，HRS-6209胶囊、HRS-4508片收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展临床试验。通知书明确：HRS-6209联合其他抗肿瘤治疗在晚期不可切除或转移性乳腺癌，或HRS-9813在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效的开放、多中心Ib/II期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866721614.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866721614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997244956.HKD","BK1191","IBBJ","MDTX","PSYK","BK0183","LU2580892789.USD","LU1969619763.USD","01276","LU1255011170.USD","BK0060","LU1655091616.SGD","LU2495084118.USD","BK0196","LU2097828474.EUR","LU1328615791.USD","LU1064130708.USD","LU0359201612.USD","LU1997245094.SGD","LU2328871848.SGD","IBBQ","LU1023057109.AUD","LU2097828805.USD","BMED","LU1146622755.USD","LU0405327494.USD","LU2289578879.USD","600276","LU2543165471.USD","BK0188","LU1580142542.USD","LU0359202008.SGD","LU2488822045.USD","BK0028","BK0012","LU1820825898.SGD","LU0359201885.HKD","LU2580892862.HKD","BK0239","LU1781817850.SGD","LU2148510915.USD","LU0405327148.USD","LU2097828631.EUR","LU2097828714.EUR","LU1997245177.USD","LU1064131003.USD","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665175368","title":"8月A股回购图谱：277家公司斥资超130亿元实施回购，超半数公司月涨幅跑赢上证指数，高争民爆单月上涨68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665175368","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665175368?lang=zh_cn&edition=full","pubTime":"2026-09-05 16:53","pubTimestamp":1788598380,"startTime":"0","endTime":"0","summary":"据同花顺iFinD数据，8月共有约277家公司实施回购，单月回购金额合计超130亿元，其中美的集团等龙头公司领衔回购金额榜。值得关注的是，这些实施回购的公司中，约半数公司8月股价涨幅跑赢上证指数，其中高争民爆单月大涨约68%，最新股价较回购成本价已大幅攀升。美的集团以10.46亿元的单月回购金额位居榜首。截至8月底，公司已累计回购80.2亿元，超过拟回购金额下限。9月4日股价为61元，较回购成本价已上涨约64%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2026-09-05/doc-iniquims0403696.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-09-05/doc-iniquims0403696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245094.SGD","LU2778985437.USD","LU2328871848.SGD","LU0228659784.USD","IE00B031HY20.USD","BK0070","IE00B031J352.USD","LU2097828474.EUR","BK0278","IE00B8L5B284.USD","LU0405327494.USD","LU0784639295.USD","BK0028","LU1366334578.USD","LU0572940350.SGD","BK0188","LU2580892789.USD","LU1130305938.SGD","LU0862451837.USD","LU2506952253.HKD","LU0264606111.USD","BK0175","IE0009570106.USD","IE0003851619.USD","LU1146622755.USD","LU0210527791.USD","IE00B8HQ1Z84.USD","LU1655091616.SGD","BK0196","IE0032834883.USD","LU0955669360.SGD","LU1997244956.HKD","LU2148510915.USD","LU0880133367.SGD","LU2097828714.EUR","BK0012","LU1568876335.HKD","LU1580142542.USD","LU1039395188.USD","LU2097828631.EUR","LU0117844026.USD","LU2476274308.USD","LU0320764599.SGD","LU1064131003.USD","LU0405327148.USD","LU2097828805.USD","LU2213484517.USD","IE00BZ08YS42.EUR","BK0061","BK0060","LU0456842615.SGD","BK0056","002827","IE0005HP3H50.USD","LU1993786604.SGD","LU1820825898.SGD","000001","LU0890818403.SGD","LU1328615791.USD","LU0955623706.USD","LU2495084118.USD","LU1969619763.USD","600227","IE00BZ08YT58.USD","LU0501845795.SGD","LU0052750758.USD","LU1781817850.SGD","IE00B0JY6N72.USD","LU0396098781.USD","LU0898667661.SGD","LU1255011170.USD","IE0003795394.USD","BK0224","LU0831103253.SGD","LU0231483743.USD","IE00BPRC5H50.USD","LU1979443071.USD","LU1807302812.USD","IE00B067MR52.USD","BK0229","BK0066","BK0077","000333","LU1655091459.SGD","LU0823437842.USD","LU1568876251.USD","LU1064130708.USD","IE00B543WZ88.USD","LU1997245177.USD","BK0183","IE0008368742.USD","LU0791590937.USD","00300","LU1934453819.USD","IE00B5MMRT66.SGD","LU0072913022.USD","LU0955648018.USD","LU0708995583.HKD","IE00B031HW06.USD","LU2097828557.USD","LU0067412154.USD","IE00BKZH1Z71.USD","LU0828238088.HKD","LU2488822045.USD","BK0033","LU0269904917.USD","BK0214","LU0572939691.SGD","IE0008368411.USD","LU0509642566.USD","LU1675838814.USD","LU0791591158.USD","IE0031814852.USD","LU2289578879.USD","BK0187","LU0593848301.USD","IE00B29SXG58.USD","IE00B97KM107.HKD","IE00BZ08YR35.GBP","LU2580892862.HKD","BK0239","600276","LU1226287529.USD","01276","002913","BK0026","LU1366334651.USD","BK0201","LU1048484197.HKD","LU0862451753.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382964","title":"1/GIP赛道竞争加剧，恒瑞医药HRS-9531值多少钱？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382964","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664382964?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:24","pubTimestamp":1788506640,"startTime":"0","endTime":"0","summary":"两大适应症剔除重叠人群后，HRS-9531的国内潜在目标患者总人数约7300万人。综合竞争格局与企业商业化能力，给予HRS-9531 40%的市场占有率假设。从临床数据质量看，根据恒瑞医药披露的III期临床数据，HRS-9531注射液治疗2型糖尿病的III期临床试验中，4mg剂量组HbA1c平均降幅达2.78%，头对头非劣于司美格鲁肽注射液1mg组，且高剂量组显示出优效性趋势。基于以上参数计算，HRS-9531大中华区峰值年销售额约为118亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-04/doc-iniqryes4102586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","LU1023057109.AUD","LU1255011170.USD","LU1580142542.USD","LU2495084118.USD","BK0239","LU1997245094.SGD","LU1997244956.HKD","LU1146622755.USD","LU2328871848.SGD","BK0012","LU2289578879.USD","LU2097828474.EUR","LU1781817850.SGD","LU2097828557.USD","LU2488822045.USD","LU1328615791.USD","LU2580892789.USD","BK0060","LU1997245177.USD","BK0188","LU2097828714.EUR","LU2148510915.USD","LU0359201885.HKD","LU1064131003.USD","BK1191","LU1969619763.USD","LU1820825898.SGD","LU2097828805.USD","LU0359202008.SGD","LU0359201612.USD","BK0183","BK0196","LU1064130708.USD","LU2580892862.HKD","LU0405327494.USD","LU1655091616.SGD","600276","LU2097828631.EUR","LU2543165471.USD","LU0405327148.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","IE00B0JY6N72.USD","01951","KURE","09926","LU0315179316.USD","01276","LU0039217434.USD","03329","06160","02269","03759","LU1242518857.USD","HK0000320264.USD","01952","HK0000306685.HKD","02162","LU0327786744.USD","02268","BK1161","BK1589","01530","02596","BK1515","01093","06821","IE00B543WZ88.USD","LU0588546209.SGD","09966","BK1209","SG9999004220.SGD","06990","03692","LU0307460666.USD","02096","LU1251922891.USD","06996","KCE","LU2543165471.USD","LU1880383366.USD","LU0348783233.USD","IE00B5MMRT66.SGD","01177","06078","02273","LU1152091168.USD","LU0856984785.SGD","09996","01548","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111348962","title":"恒瑞医药（01276）获批奥特康唑胶囊境内生产注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1111348962","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111348962?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:56","pubTimestamp":1788443784,"startTime":"0","endTime":"0","summary":"2026年9月3日，江苏恒瑞医药股份有限公司（01276）公告称，其子公司成都盛迪医药有限公司已收到国家药品监督管理局批准，奥特康唑胶囊（0.15g，化学药品4类）取得境内生产药品注册上市许可，适应症为治疗重度外阴阴道假丝酵母菌病（VVC）。\\n\\n该品种源自美国Mycovia公司，为选择性真菌CYP51抑制剂。此前，以境外生产形式已于2023年在中国获批上市，本次为生产转移至境内。\\n\\n公告显示，奥特康唑胶囊累计研发投入约2.19亿元（未经审计）。全球同类产品2025年合计销售额约22.30亿美元。\\n\\n恒瑞医药提示，药品投产及销售仍可能受到不确定因素影响，提醒投资者关注风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174537853","title":"恒瑞医药(01276)口服GLP-1新药HRS-7535片上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1174537853","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174537853?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:45","pubTimestamp":1788443139,"startTime":"0","endTime":"0","summary":"2026年9月3日，江苏恒瑞医药股份有限公司公告称，其控股子公司山东盛迪医药有限公司已收到国家药品监督管理局下发的《受理通知书》，HRS-7535片的药品上市许可申请正式获受理。本次申报的HRS-7535片为口服小分子胰高血糖素样肽-1受体激动剂，剂型为片剂。上市申请基于一项编号为HRS-7535-303的关键Ⅲ期多中心、随机、双盲、安慰剂对照、平行设计临床试验结果。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114055611","title":"恒瑞医药(01276)：自主创新生物药SHR-1819上市申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1114055611","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114055611?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:45","pubTimestamp":1788443136,"startTime":"0","endTime":"0","summary":"2026年9月3日，江苏恒瑞医药股份有限公司公告称，其子公司广东恒瑞医药有限公司已收到国家药品监督管理局签发的《受理通知书》，针对卓托奇拜单抗注射液的药品上市许可申请被正式受理，受理号为CXSS2600144，拟定适应症为“治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎”。\\n\\n本次上市申请依据的关键数据来自一项多中心、随机、双盲、安慰剂对照的Ⅲ期临床研究。\\n\\n截至公告披露日，公司在SHR-1819项目上的累计研发投入约38,570万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.2082},{"period":"3month","weight":-0.1398},{"period":"6month","weight":-0.2871},{"period":"1year","weight":-0.4608},{"period":"ytd","weight":-0.3476}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}